|Table of Contents|

Trend of survival rate of malignant tumor among 15~39-year-old population in Qidong

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 08
Page:
1542-1547
Research Field:
Publishing date:

Info

Title:
Trend of survival rate of malignant tumor among 15~39-year-old population in Qidong
Author(s):
WANG Jun; CHEN Yongsheng; ZHU Jian; DING Lulu; ZHANG Yonghui; XU Yuanyou; CHEN Jianguo; QU Kaiquan
Department of Etiology,Qidong People's Hospital,Qidong Liver Cancer Institute,Qidong Hospital Affiliated to Nantong University,Jiangsu Qidong 226200,China.
Keywords:
cancer; survival rate; trends; 15~39-year-old; Qidong
PACS:
R730.7
DOI:
10.3969/j.issn.1672-4992.2023.08.028
Abstract:
Objective:To analyze the survival of cancer among 15~39-year-old population in Qidong from 1972 to 2016,and provide a basis for the prognosis evaluation and prevention of cancer among 15~39-year-old patients.Methods:The data of cancer was obtained from the Qidong Cancer Registration and Reporting System,and the follow-up was up to December 31,2021.Observed survival rate (OSR) and relative survival rate (RSR) were calculated by SURV3.01 software,and Hakulinen's likelihood ratio test was used for statistical difference comparison.Joinpoint 4.7.0.0 software was used to conduct the annual percentage change (APC) of cancer survival rate among 15~39-year-old population.Results:During 1972 to 2016,the OSR of cancer among 15~39-year-old at 1,5 and 10 years were 32.75%,18.95% and 16.30%,and the RSR at 1,5 and 10 years were 32.82%,19.19% and 16.80%,respectively.Dividing 1972-2016 into 9 periods,the 5-RSR increased from 13.65% in 1972-1976 to 56.47% in 2012-2016.The uptrends of RSR in the nine periods were statistically significant (χ2=869.73,P＜0.001).The APC of 5-OSR and 5-RSR were 4.25% and 4.22% from 1972 to 2016 in Qidong,the upward trend was statistically significant in both 5-OSR and 5-RSR (both P＜0.05).The 5-OSR and 5-RSR for male were 10.57% and 10.74%,and for female were 33.83% and 34.05%.The survival rate of female was higher than that of male,there was a statistically significant difference in RSR between male and female (χ2=957.32,P＜0.001).The 5-RSR for the age groups of 15~19,20~24,25~29,30~34,and 35~39 years old were 19.69%,21.93%,19.53%,19.14%and 18.67%,respectively.There was no significant difference in RSR among different age groups (χ2=50.34,P=0.127).Moreover,the APC of 5-RSR among 15~19,20~24,25~29,30~34,and 35~39 years old were 2.99%,3.51%,4.82%,4.73%and 4.07%,respectively.The increasing trend of 5-RSR in each age group was statistically significant (all P＜0.05).Among the top ten cancer,the highest 5-RSR was thyroid cancer (97.80%),followed by cervical cancer (74.61%) and female breast cancer (68.22%),the lowest 5-RSR was liver cancer (4.54%),and followed by lung cancer (12.28%) and leukemia (12.75%).From 1972 to 2016,liver cancer accounted for 55.07% of all cancer among 15~39-year-old in Qidong,and its 5-RSR increased from 2.87% in 1972-1986 to 9.13% in 2002-2016.Conclusion:Over the past 45 years,the overall survival rate of cancer among 15~39-year-old in Qidong has been on the rise,but there's still a certain room for improvement.It is necessary to pay more attention to the early diagnosis,early treatment and health education of 15~39-year-old population,so as to improve the survival rate of cancer among 15~39-year-old.

References:

［1］ 郑荣寿,孙可欣,张思维,等.2015 年中国恶性肿瘤流行情况分析［J］.中华肿瘤杂志,2019,41(1):19-28. ZHENG RS,SUN KX,ZHANG SW,et al.Report of cancer epidemiology in China,2015［J］.Chinese Journal of Oncology,2019,41(1):19-28.
［2］ ZHENG RS,ZHANG SW,ZENG HM,et al.Cancer incidence and mortality in China,2016［J］.Journal of the National Cancer Center,2022,2(1):1-9.
［3］ IARC.Estimated number of new cases in 2020,World,both sexes,ages 15~39 (excl.NMSC)［Z/OL］.International Agency for Research on Cancer,2020.
［2022-08-08］.https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_grouP=0&ages_group%5B%5D=3&ages_group%5B%5D=7&group_cancer=1&include_nmsc=0&include_nmsc_other=1.
［4］ BRAY F,COLOMBET M,MERY M,et al.Cancer incidence in five continents［M］.Lyon:IARC,2021:1-1545.
［5］ 赫捷.2018中国肿瘤登记年报［M］.北京:人民卫生出版社,2019:1-637. HE J.China cancer registry annual report,2018［M］.Beijing:People' Medical Publishing House,2019:1-637.
［6］ MILLER KD,FIDLER-ENAOUDIA M,KEEGAN TH,et al.Cancer statistics for adolescents and young adults,2020［J］.CA:A Cancer Journal for Clinicians,2020,70(6):443-459.
［7］ PARK M,LIM J,LEE JA,et al.Cancer incidence and survival among adolescents and young adults in Korea:an update for 2016［J］.Cancer Research and Treatment,2021,53(1):32-44.
［8］ MURPHY CC,LUPO PJ,ROTH ME,et al.Disparities in cancer survival among adolescents and young adults:A population-based study of 88 000 patients［J］.JNCI:Journal of the National Cancer Institute,2021,113(8):1074-1083.
［9］ SEER.All cancer sites combined SEER 5-year relative survival rates,2012-2018［Z/OL］.USA:National Cancer Institute,2019.
［2022-08-08］.https://seer.cancer.gov/statistics-network/explorer/application.html?site=1&data_type=4&graph_type=5&compareBy=sex&chk_sex_3=3&chk_sex_2=2&series=9&race=1&age_range=62&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0#graphArea.
［10］ 中国疾病预防控制中心慢性非传染性疾病预防控制中心.中国慢性病及其危险因素监测报告2018［M］.北京:人民卫生出版社,2021:36-55. NCNCD of China CDC.Report on chronic disease risk factor surveillance in China,2018［M］.Beijing:People' Medical Publishing House,2021:36-55.
［11］ WHO.Noncommunicable Diseases Country Profiles 2018［Z/OL］.Geneva:WHO,2018.
［2022-08-08］.https://www.who.int/publications/i/item/ncd-country-profiles-2018.
［12］ TRAMA A,BOTTA L,FOSCHI R,et al.Survival of European adolescents and young adults diagnosed with cancer in 2000-07:population-based data from EUROCARE-5［J］.The Lancet Oncology,2016,17(7):896-906.
［13］ OHARA A,FURUI T,SHIMIZU C,et al.Current situation of cancer among adolescents and young adults in Japan［J］.International Journal of Clinical Oncology,2018,23(6):1201-1211.
［14］ ZENG H,CHEN W,ZHENG R,et al.Changing cancer survival in China during 2003-15:a pooled analysis of 17 population-based cancer registries［J］.The Lancet Global Health,2018,6(5):e555-e567.
［15］ MOKE DJ,TSAI K,HAMILTON AS,et al.Emerging cancer survival trends,disparities,and priorities in adolescents and young adults:A California cancer registry-based study［J］.JNCI Cancer Spectrum,2019,3(2):pkz031.
［16］ 陈建国,朱源荣.党旗引领下的肿瘤防治研究:启东肝癌防治现场研究50年掠影［J］.中国肿瘤,2021,30(08):561-575. CHEN JG,ZHU YR.Fifty years of review of field work on control and prevention of liver cancer in Qidong［J］.China Cancer,2021,30(08):561-575.
［17］ CHEN JG,ZHU J,ZHANG YH,et al.Liver cancer survival:A real world observation of 45 years with 32,556 cases［J］.Journal of Hepatocellular Carcinoma,2021,8:1023-1034.
［18］ LIANG F,MA F,ZHONG J.Prognostic factors of patients after liver cancer surgery:Based on surveillance,epidemiology,and end results database［J］.Medicine,2021,100(30):1-6.
［19］王艳,郭志,杨雪玲,等.85例青年原发性肝癌的临床病理特征及预后因素分析［J］.天津医科大学学报,2018,24(06):505-508. WANG Y,GUO Z,YANG XL,et al.Clinicopathological features and prognosis of 85 young patients with primary hepatic carcinoma［J］.Journal of Tianjin Medical University,2018,24(06):505-508.

Memo

Memo:
2022年江苏省南通市科技计划项目（编号：JCZ2022050）
Last Update: 1900-01-01